SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE

Protocol No

RHEU-ABBVIE-SELECT-SLE

Staff Member

David Gazeley

Phase

III

Summary

This project is being done to assess the safety and efficacy of upadacitinib compared with placebo for the treatment of signs and symptoms in adults with moderately to severely active systemic lupus erythematosus.

Objective

Oral Upadacitinib in Adults with Mild to Moderate SLE

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL